Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CBIONASDAQ:MACKNASDAQ:MTEMNASDAQ:RGLS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCatalyst Biosciences$0.77$0.19▼$8.69$291.29M1.05763,526 shs32,246 shsMACKMerrimack Pharmaceuticals$14.84+0.6%$14.23$11.53▼$15.89$215.63M1.44107,717 shs31,183 shsMTEMMolecular Templates$2.35-0.4%$3.35$1.68▼$9.45$12.62M1.220,869 shs317,865 shsRGLSRegulus Therapeutics$2.85-1.0%$1.68$0.78▼$3.79$57.63M1.453.07 million shs172,656 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCatalyst Biosciences0.00%0.00%0.00%0.00%+3,936.58%MACKMerrimack Pharmaceuticals+0.20%+0.41%+0.34%+10.65%+21.90%MTEMMolecular Templates+2.62%+34.29%-40.05%-37.67%-52.74%RGLSRegulus Therapeutics+1.23%+15.20%+102.82%+128.57%+246.78%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBIOCatalyst BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AMACKMerrimack Pharmaceuticals1.0971 of 5 stars0.03.00.00.02.65.00.0MTEMMolecular Templates3.3594 of 5 stars0.05.00.04.64.12.50.6RGLSRegulus Therapeutics3.0464 of 5 stars4.42.00.00.03.12.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBIOCatalyst BiosciencesN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/ARGLSRegulus Therapeutics2.80Moderate Buy$7.25154.39% UpsideCurrent Analyst RatingsLatest MACK, CBIO, MTEM, and RGLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/19/2024RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.003/18/2024RGLSRegulus TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/18/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/18/2024RGLSRegulus TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.003/13/2024RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $3.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBIOCatalyst Biosciences$790K0.00N/AN/A($0.78) per share0.00MACKMerrimack PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AMTEMMolecular Templates$19.75M0.64N/AN/A($4.03) per share-0.58RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBIOCatalyst Biosciences-$8.24M-$1.38N/AN/AN/AN/A-364.68%-281.68%4/4/2024 (Estimated)MACKMerrimack Pharmaceuticals-$1.18M-$0.08N/A∞N/AN/A-6.24%-6.09%5/2/2024 (Estimated)MTEMMolecular Templates-$92.72M-$6.67N/AN/AN/A-49.57%N/A-43.85%4/4/2024 (Estimated)RGLSRegulus Therapeutics-$30.04M-$1.59N/AN/AN/AN/A-109.21%-80.55%5/9/2024 (Estimated)Latest MACK, CBIO, MTEM, and RGLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023RGLSRegulus Therapeutics-$0.40-$0.40N/A-$0.40N/AN/A3/7/2024Q4 2023MACKMerrimack PharmaceuticalsN/A-$0.01-$0.01-$0.01N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBIOCatalyst BiosciencesN/AN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBIOCatalyst BiosciencesN/A2.882.88MACKMerrimack PharmaceuticalsN/A43.5043.50MTEMMolecular TemplatesN/A1.061.06RGLSRegulus TherapeuticsN/A3.313.31OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBIOCatalyst Biosciences5.98%MACKMerrimack Pharmaceuticals63.97%MTEMMolecular Templates95.47%RGLSRegulus Therapeutics92.38%Insider OwnershipCompanyInsider OwnershipCBIOCatalyst Biosciences2.92%MACKMerrimack Pharmaceuticals28.87%MTEMMolecular Templates18.70%RGLSRegulus Therapeutics8.41%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCBIOCatalyst Biosciences737.98 million36.87 millionOptionableMACKMerrimack Pharmaceuticals42614.53 million10.34 millionOptionableMTEMMolecular Templates1115.37 million4.37 millionOptionableRGLSRegulus Therapeutics3020.22 million18.52 millionOptionableMACK, CBIO, MTEM, and RGLS HeadlinesSourceHeadlineRegulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Up 9,244.3% in Marchamericanbankingnews.com - March 28 at 2:40 AMShort Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Expands By 9,244.3%marketbeat.com - March 27 at 10:53 AMHC Wainwright Comments on Regulus Therapeutics Inc.'s Q1 2024 Earnings (NASDAQ:RGLS)americanbankingnews.com - March 27 at 6:00 AMRegulus Therapeutics (NASDAQ:RGLS) Rating Reiterated by HC Wainwrightamericanbankingnews.com - March 26 at 3:34 AMBuy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development Milestonesmarkets.businessinsider.com - March 26 at 3:28 AMRegulus Therapeutics (NASDAQ:RGLS) Given "Buy" Rating at HC Wainwrightmarketbeat.com - March 25 at 8:21 AMRegulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancementsfinance.yahoo.com - March 23 at 10:30 AMRegulus Therapeutics (NASDAQ:RGLS) Coverage Initiated by Analysts at StockNews.comamericanbankingnews.com - March 23 at 2:48 AMRegulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updatesfinanznachrichten.de - March 22 at 7:21 AMRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023investorplace.com - March 21 at 11:00 PMRegulus: Q4 Earnings Snapshottimesunion.com - March 21 at 9:20 PMRegulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updatesfinance.yahoo.com - March 21 at 4:20 PMRegulus Therapeutics (NASDAQ:RGLS) Given New $11.00 Price Target at Canaccord Genuity Groupamericanbankingnews.com - March 21 at 4:58 AMRegulus Therapeutics Inc. (NASDAQ:RGLS) Receives $7.50 Consensus Price Target from Brokeragesamericanbankingnews.com - March 21 at 3:34 AMQ1 2024 EPS Estimates for Regulus Therapeutics Inc. Increased by Analyst (NASDAQ:RGLS)americanbankingnews.com - March 20 at 6:50 AMRegulus Therapeutics Inc. (NASDAQ:RGLS) Expected to Post FY2023 Earnings of ($1.60) Per Shareamericanbankingnews.com - March 20 at 6:50 AMRegulus Therapeutics (NASDAQ:RGLS) Receives "Outperform" Rating from Leerink Partnrsamericanbankingnews.com - March 20 at 6:04 AMAnalysts Set Expectations for Regulus Therapeutics Inc.'s FY2025 Earnings (NASDAQ:RGLS)americanbankingnews.com - March 20 at 4:27 AMBuy Rating Affirmed for Regulus Therapeutics on Promising RGLS8429 ADPKD Treatment Datamarkets.businessinsider.com - March 19 at 11:39 PMRegulus Therapeutics (NASDAQ:RGLS) Given Buy Rating at HC Wainwrightamericanbankingnews.com - March 19 at 5:26 AMRegulus Therapeutics (NASDAQ:RGLS) Now Covered by Analysts at SVB Leerinkamericanbankingnews.com - March 19 at 4:40 AMRGLS Mar 2024 7.500 putfinance.yahoo.com - March 15 at 5:16 AMBiotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & Morefinance.yahoo.com - March 14 at 2:15 PM$100 million fundraise for antisense firm working in nephrologythepharmaletter.com - March 13 at 7:40 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCatalyst BiosciencesNASDAQ:CBIOCatalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.Merrimack PharmaceuticalsNASDAQ:MACKMerrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Molecular TemplatesNASDAQ:MTEMMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.Regulus TherapeuticsNASDAQ:RGLSRegulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.